Inhibrx Inc
NASDAQ:INBX

Watchlist Manager
Inhibrx Inc Logo
Inhibrx Inc
NASDAQ:INBX
Watchlist
Price: 79.475 USD 5.83% Market Closed
Market Cap: 1.2B USD

Operating Margin

-7 937.8%
Current
Improving
by 22 059.1%
vs 3-y average of -29 996.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-7 937.8%
=
Operating Income
$-111.1m
/
Revenue
$1.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-7 937.8%
=
Operating Income
$-111.1m
/
Revenue
$1.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Inhibrx Inc
NASDAQ:INBX
1.1B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
386.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.4B USD
Loading...

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4th
Based on 14 112 companies
4th percentile
-7 937.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Inhibrx Inc
Glance View

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.

INBX Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-7 937.8%
=
Operating Income
$-111.1m
/
Revenue
$1.4m
What is Inhibrx Inc's current Operating Margin?

The current Operating Margin for Inhibrx Inc is -7 937.8%, which is above its 3-year median of -29 996.8%.

How has Operating Margin changed over time?

Over the last 3 years, Inhibrx Inc’s Operating Margin has decreased from -2 364.4% to -7 937.8%. During this period, it reached a low of -165 724% on Dec 31, 2024 and a high of -2 364.4% on Sep 30, 2022.

Back to Top